๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Osaka
Clinical trial register · Japan

Clinical Trials in Osaka, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 2472 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:48 UTC
2472
Studies in scope
all four open statuses
1255
Recruiting now
open to new participants
347
Lead sponsors
across recruiting studies
Top sites
Fukuoka 550 Nagoya 510 Sapporo 402 Tokyo 363 Osaka 345
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca18 Eli Lilly and Company16 GlaxoSmithKline15 Novartis Pharmaceuticals14 AbbVie13
Site location
Fukuoka550 Nagoya510 Sapporo402 Tokyo363 Osaka345
All 929 locations
Target enrolment
to

Trials with a site in Osaka

345 of 2472 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC
NCT07733180Advanced Esophageal Squamous Cell Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma
Drugs5-FU·Leucovorin·Adrucil·Tislelizumab
BeOne Medicines
Phase 2
30
Osaka
2026-09-14
Recruiting
A Study of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors (EMBOLD PanTumour-103)
NCT07602855Neoplasms, Lung
DrugsRisvutatug Rezetecan·Ivonescimab
GlaxoSmithKline
Phase 1/2
184
Osaka
2026-09-09
Not yet open
A Study of Mezagitamab in Adults With Late Antibody-Mediated Rejection (AMR) After a Kidney Transplant
NCT07613359Antibody-Mediated Rejection (AMR)
DrugMezagitamab
Takeda
Phase 2
36
Nagoya, Kumamoto, Shinjuku-ku, Niigata, Osaka
2026-09-01
Recruiting
A Phase 2 Study of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection With Hemophilia
NCT07681089Liver Cirrhosis
Kiminori Kimura, MD
Phase 2
4
Sapporo, Osaka, Bunkyo-Ku
2026-09-01
Not yet open
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
NCT07668336Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly and Company
Phase 3
170
Chiyoda-ku, Fukuoka, Iruma, Moriyama, Niigata, Osaka, Saitama, Sendai
2026-09
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugAZD6234
AstraZeneca
Phase 3
2,500
Chลซลku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
2026-08-19
Recruiting
A Phase 2 Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer
NCT07766018Breast Cancer
DrugElacestrant
Stemline Therapeutics, Inc.
Phase 2
70
Chiba, Fukuoka, Ina, Isehara, Kลtล City, Kumamoto, Osaka, Sapporo
2026-08-18
Recruiting
A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.
NCT07734116Pediatric Malignant Solid Tumor and Epithelioid Sarcoma
DrugONO-4538HSC
Ono Pharmaceutical Co., Ltd.
Phase 1/2
50
Chiba, Fukuoka, Hiroshima, Sapporo, Yokohama, Kyoto, Osaka, Sunto-gun
2026-08-18
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity With Treatment Combinations With Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary Cancers
NCT07769502Pancreatobiliary Cancers, Pancreatic Ductal Adenocarcinoma
DrugsTelisotuzumab Adizutecan·Nab-paclitaxel·Gemcitabine
AbbVie
Phase 2
168
Yokohama, Osaka, Chuo-Ku
2026-08-17
Recruiting
A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT07759245Pulmonary Disease, Chronic Obstructive
DrugBrenipatide
Eli Lilly and Company
Phase 2
606
Chลซลku, Fukuoka, Iizuka, Osaka, Sendai, Ube
2026-08-07
Recruiting
First-in-Human Trial of DS1025a in Participants With Advanced Solid Tumors
NCT07681882Advanced Solid Tumor, Metastatic Solid Tumor, Unresectable Solid Tumor
Daiichi Sankyo
Phase 1
45
Kashiwa, Osaka, Tokyo
2026-08-06
Recruiting
A Study of IBI3016 in Japanese Participants
NCT07838220Hypertension
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1
30
Osaka
2026-08-01
Recruiting
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT07701967Nasal Polyps
DrugDepemokimab
GlaxoSmithKline
Phase 4
28
Ehime, Fukui, Fukuoka, Gunma, Nagano, Osaka, Saitama, Shiga
2026-07-15
Recruiting
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
NCT07682961HIV Infections
DrugsTeropavimab·Zinlirvimab·Rilpivirine·Cabotegravir
Gilead Sciences
Phase 3
590
Osaka
2026-07-14
Recruiting
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
NCT07503444Rett Syndrome
UCB BIOSCIENCES, Inc.
Phase 3
200
Kodaira, Kurume, Musashimurayama-shi, Osaka, Setagaya-ku
2026-07-14
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
DrugPF-08634404
Pfizer
Phase 2
40
Hirakata, Chลซล, Kotoku, Osaka
2026-07-02
Recruiting
A Post-Marketing Clinical Trial of Pemafibrate in Patients ๏ฝ—ith Hypercholesterolemia and Inadequate Response to Statins
NCT07634484Hypercholesterolemia
DrugPemafibrate
Kowa Company, Ltd.
Phase 4
120
Hokkaido, Ibaraki, Kagawa, Kanagawa, Osaka, Saitama, Tokyo
2026-07-01
Recruiting
A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed
NCT07650916HIV Infections
DrugsCab Ula·Rpv La·Cabotegravir
ViiV Healthcare
Phase 3
564
Aichi, Kanagawa, Osaka, Tokyo
2026-06-25
Recruiting
Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer
NCT07710885Biliary Tract Cancer
DrugsFutibatinib·Zimberelimab·Durvalumab·Gemcitabine
Taiho Pharmaceutical Co., Ltd.
Phase 3
784
Aichi, Fukuoka, Hokkaido, Kanagawa, Miyagi, Osaka, Tokyo, Toyama
2026-06-24
Recruiting
A Study of ONO-7429 in Participants With Unresectable Advanced or Recurrent Solid Tumors
NCT07787208Solid Tumors
Ono Pharmaceutical Co., Ltd.
Phase 1
80
Kashiwa, Maebashi, Niigata, Hirakata, Osaka, Sakai, Hidaka, Sunto-gun
2026-06-19
Recruiting
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
NCT07286266Ovarian Neoplasms
DrugsMocertatug rezetecan·Pegylated liposomal doxorubicin·Topotecan·Gemcitabine
GlaxoSmithKline
Phase 3
450
Hyลgo, Osaka
2026-06-18
Recruiting
Comparison of Operator Radiation Exposure During Percutaneous Coronary Intervention Between Left Distal and Right Conventional Radial Access
NCT07579169Radiation Exposure
Yonsei University
Not applicable
748
Osaka
2026-06-18
Recruiting
Comparison of Anti-Thrombotic Treatments Between Aspirin and Warfarin During Initial Six Months After Bioprosthetic Heart Valve Replacement
NCT07431762Valve Replacement Surgery
DrugsWarfarin·Aspirin
Asan Medical Center
Phase 4
1,058
Osaka
2026-06-05
Recruiting
A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07577856Colitis, Ulcerative
DrugsJNJ-78934804·Tremfya·Guselkumab
Janssen Research & Development, LLC
Phase 3
644
Hamamatsu, Higashi-Ibaraki, Kagoshima, Kashiwa, Kumamoto, Minatoku, Nagakute, Osaka
2026-05-23
Recruiting
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
NCT07525206Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 3
990
Kashiwa-shi, Matsuyama, Kobe, Kawasaki-shi, Osaka, Koto-ku
2026-05-22
Recruiting
A Study of TAK-755 in Adults With Acute Ischemic Stroke
NCT07392450Acute Ischemic Stroke
DrugTAK-755
Takeda
Phase 2
222
Fukuoka, Nagano, Izumisano, Osaka
2026-05-17
Recruiting
A Study to Assess the Effectiveness and Safety of Canakinumab in Clinical Use in Patients With Schnitzler's Syndrome
NCT07598422Schnitzler Syndrome
Novartis Pharmaceuticals
Observational
10
Kobe, Ushiku, Kanoya, Yokohama, Osaka
2026-05-13
Recruiting
AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea
NCT07571109Obesity, Overweight, Obstructive Sleep Apnoea
DrugNNC0487-0111
Novo Nordisk A/S
Phase 3
300
Fukuoka, Hiroshima, Kumamoto, Okinawa, Osaka, Sapporo-shi, Hokkaido, Shizuoka, Tokyo
2026-05-05
Recruiting
Exploratory Study of ADR-002K for Heart Failure Patients With Ischemic Heart Disease Who Undergo CABG
NCT07192211Ischemic Heart Disease
Rohto Pharmaceutical Co., Ltd.
Phase 2
50
Osaka
2026-04-28
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
NCT07502443Narcolepsy Type 2
DrugAlixorexton
Alkermes, Inc.
Phase 3
176
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-ku
2026-04-22
Recruiting
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
NCT07441876Achondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2/3
160
Hokkaido, Osaka, Tokyo
2026-04-20
Recruiting
Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)
NCT07258069Subdural Hematoma, Subdural Hematoma, Chronic
Aesculap AG
Observational
178
Kobe, Fukuoka, Okayama, Kyoto, Osaka-Fu, Osaka
2026-04-10
Recruiting
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
NCT07522073Solid Tumors
DrugINCB161734
Incyte Corporation
Phase 3
588
Akashi, HYGO, Fukuoka Fukuoka, Kahoku-gun, Kitaadachi-gun, Kลtoku, Mitaka-shi, Osaka, Sapporo Hokkaido
2026-04-09
Recruiting
A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
NCT07455383Narcolepsy Type 1
DrugAlixorexton
Alkermes, Inc.
Phase 3
150
Kitakyushu-shi, Osaka, Shibuya-ku, Shinjuku-Ku, Kumamoto
2026-04-06
Recruiting
TAMBE Japan Post-Marketing Surveillance
NCT07147569Thoracoabdominal Aortic Aneurysm, Pararenal Aortic Aneurysm
W.L.Gore & Associates
Observational
100
Minatoku, Nagoya, Osaka, Suita
2026-03-27
Recruiting
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
NCT06947941Alzheimer Disease, Psychosis
DrugsKarX-EC·KarXT
Bristol-Myers Squibb
Phase 3
325
Suita, Nankoku-shi, Osaka
2026-03-25
Recruiting
A Non-Interventional Study PASS to Characterize Secondary Malignancies of Tcell Origin Following Tisagenlecleucel Therapy
NCT07378969Secondary Malignancies of T-cell Origin
Novartis Pharmaceuticals
Observational
30
Kurume, Osaka, Suita, Bunkyo Ku
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT07351058Obesity or Overweight, Type 2 Diabetes Mellitus
Hoffmann-La Roche
Phase 3
1,600
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-23
Recruiting
Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial
NCT07293260Cardiovascular Disease
DrugOlpasiran
Amgen
Phase 3
406
Tomakomai-shi, Osaka, Chuo-shi
2026-03-23
Recruiting
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
NCT07351045Obesity or Overweight
Hoffmann-La Roche
Phase 3
2,000
Aichi, Fukuoka, Hokkaido, Osaka, Tokyo
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
DrugsPumitamig·Folfox·Nivolumab
Bristol-Myers Squibb
Phase 2/3
690
Nagoya, Chiba, Kashiwa, Matsuyama, Yokohama, Kurashiki, Osaka, Suita
2026-03-13
Recruiting
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
1,182
Minami-ku, Nagoya-shi, Nagoya, Fukuoka, Tsu, Mie, Sasebo-shi, Osaka, Chuo-ku, Meguro-Ku
2026-03-11
Active, closed
A Study to Assess a Medicine Called Tovorafenib in Japanese Children and Young Adults With Brain Tumours
NCT07441707Low-grade Glioma
DrugTovorafenib
Ipsen
Phase 1
6
Kanagawa, Kobe, Kyoto, Osaka, Tokyo
2026-03-10
Recruiting
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
NCT07491445Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma
DrugsCetuximab·Nab-paclitaxel·Gemcitabine
Revolution Medicines, Inc.
Phase 3
900
Kashiwa, Koto-Ku, Chiba, Fukuoka, Kanagawa, Osaka, Tokyo, Wakayama
2026-03-09
Recruiting
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naรฏve Persons With HIV-1 (INNOVATE Study)
NCT07202546HIV Infections
DrugsVH4524184·Dolutegravir/Lamivudine
ViiV Healthcare
Phase 2
186
Fukuoka, Kanagawa, Okinawa, Osaka, Tokyo
2026-02-11
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT07369011Sleep Apnea, Obstructive, Obesity, Overweight
DrugEloralintide
Eli Lilly and Company
Phase 3
800
Bunkyล City, Fukuoka, Kitahiroshima, Kitakyushu, Minatoku, Osaka, Sapporo, Shibuya-ku
2026-02-10
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Chลซลku, Izumisano, Kawasaki, Kisarazu, Kure, Kyoto, Matsuyama, Osaka
2026-02-10
Recruiting
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
NCT07222332Diabetes Mellitus, Type 1
DrugBaricitinib
Eli Lilly and Company
Phase 3
300
Ichikawa, Iruma, Moriyama, Osaka, Sendai, Shizuoka
2026-02-05
Recruiting
Comparison of Weekly Somatrogon to Daily Genotropin in Children Born Small for Gestational Age or With Idiopathic Short Stature.
NCT07226089ISS, SGA
DrugSomatrogon
Rabin Medical Center
Phase 3
254
Izumi-Shi, Nara, Osaka, Setagaya-Ku
2026-02-01
Recruiting
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT07321873Arthritis, Psoriatic
Janssen Research & Development, LLC
Phase 2
240
Fuchลซ, Kagoshima, Kitakyushu-shi, Osaka, Sanuki, Shimonoseki
2026-01-15
Recruiting
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
NCT07174427Synovial Sarcomas
DrugsTBI-1301·Fludarabine·Cyclophosphamide
Takara Bio Inc.
Phase 3
5
Osaka, Fukuoka
2026-01-05
Active, closed
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy
NCT07225686Obesity, Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-12-19
Recruiting
TBE Zone 2 PMS in Japan
NCT07049913Aneurysm Thoracic, Dissection of Aorta, Thoracic, Trauma
W.L.Gore & Associates
Observational
200
Osaka
2025-12-15
Recruiting
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
NCT07221253Biliary Tract Cancer
DrugsGemcitabine/Cisplatin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kลtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802Plaque Psoriasis
DrugZasocitinib
Takeda
Phase 3
110
Nagoya, Kitakyushu-shi, Tsu, Mie, Osaka, Itabashi-Ku
2025-12-04
Recruiting
A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)
NCT07209111Neoplasm Malignant
DrugsCalderasib·Cetuximab
Merck Sharp & Dohme LLC
Phase 2
150
Yokohama, Chลซล, Koto, Osaka
2025-12-04
Recruiting
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
NCT07218926Gastrointestinal Neoplasms
DrugsIDRX-42·Sunitinib
GlaxoSmithKline
Phase 3
450
Chiba, Ehime, Fukuoka, Hokkaido, Kanagawa, Kumamoto, Miyagi, Osaka
2025-12-03
Recruiting
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naรฏve Metastatic Castration-resistant Prostate Cancer
NCT07213674Metastatic Castration-resistant Prostate Cancer
DrugsXaluritamig·Cabazitaxel·Abiraterone acetate·Docetaxel
Amgen
Phase 3
750
Nagoya, Matsuyama, Fukuoka, Kobe, Kanazawa, Kita-gun, Sagamihara-shi, Osaka
2025-11-28
Recruiting
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
NCT07166094Endometrial Cancer, Recurrent or Progressive Endometrial Cancer
DrugRina-S
Genmab
Phase 3
660
Chiba, ลŒta, Shiwa-gun, Sagamihara-shi, Yokohama, Tsu, Sendai, Osaka
2025-11-28
Recruiting
Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy
NCT07226765Obstructive Sleep Apnea
DrugMaridebart cafraglutide
Amgen
Phase 3
250
Chikushino-shi, Fukuoka, Aki-gun, Kitahiroshima-shi, Yokohama, Kumamoto, Urasoe-shi, Osaka
2025-11-25
Active, closed
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015Atopic Dermatitis
DrugKT-621
Kymera Therapeutics, Inc.
Phase 2
200
Ichikawa, Kagoshima, Kanagawa, Nagoya, Osaka, Sakai, Sapporo
2025-11-24
Recruiting
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857Epileptic Encephalopathy
Institut de Recherches Internationales Servier
Phase 1/2
20
Nagano, Osaka, Shizuoka
2025-11-24
Active, closed
A Study to Learn About How Well BAY 3401016 Works in Adults With Alport Syndrome
NCT07211685Alport Syndrome
Bayer
Phase 2
60
Nagoya, Kobe, Chuo-Ku, Osaka
2025-11-19
Recruiting
Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer
NCT07228832Metastatic Colorectal Cancer (CRC)
DrugsLeucovorin·Ivonescimab·Adrucil·Oxaliplatin
Summit Therapeutics
Phase 3
600
Osaka, Aichi, Chiba, Ehime, Fukuoka, Gifu, Hiroshima, Hokkaido
2025-11-18
Recruiting
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivoยฎ, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer
NCT06948448Colorectal Cancer
DrugsONO-4578·Opdivo·Leucovorin·Adrucil
Ono Pharmaceutical Co., Ltd.
Phase 2
144
Hyลgo, Osaka
2025-11-18
Active, closed
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07170150Alzheimers Disease
DrugTrontinemab
Hoffmann-La Roche
Phase 3
1,060
Hiroshima, Hyลgo, Kagawa, Kochi, Okayama, Osaka, Tokyo
2025-11-12
Recruiting
LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:
NCT07186101Ulcerative Colitis
DrugsZotemtegrast·Mirikizumab
Eli Lilly and Company
Phase 2
252
Fukuoka, Kamakura, Kashiwa, Osaka, Sakura, Sapporo
2025-11-10
Recruiting
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
NCT07347314Advanced Small Bowel Adenocarcinoma
DrugEnfortumab Vedotin
National Cancer Center, Japan
Phase 2
27
Fukuoka, Osaka, Tokyo
2025-11-04
Recruiting
Navitor Japan Study
NCT07193888Severe Aortic Stenosis
Abbott Medical Devices
Observational
100
Fukuoka, Kanagawa, Osaka
2025-10-30
Active, closed
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
NCT07076121Pancreatic Ductal Adenocarcinoma
DrugsNavlimetostat·Nab-paclitaxel·Gemcitabine
Bristol-Myers Squibb
Phase 2/3
470
Nagoya, Kashiwa, Sapporo, Yokohama, Chuo-ku, Koto, Osaka
2025-10-23
Recruiting
A Study of ZW251 in Participants With Advanced Solid Tumors
NCT07164313Hepatocellular Carcinoma, Squamous Cell Non-Small Cell Lung Cancer, Germ Cell Tumor
Zymeworks BC Inc.
Phase 1
100
Kashiwa, Kyoto, Osaka, Tokyo
2025-10-21
Recruiting
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
NCT07194850Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
DrugEfgartigimod
argenx
Phase 2/3
24
Osaka
2025-10-20
Recruiting
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
NCT07213609Neoplasms, Colorectal, Neoplasms
GlaxoSmithKline
Phase 1/2
47
Chiba, Osaka, Tokyo
2025-10-20
Recruiting
A Study of JNT-517 in Participants With Phenylketonuria (PKU)
NCT06971731Phenylketonuria
DrugJNT-517
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3
120
Chiyoda-ku, Kutsukake-cho, Osaka
2025-10-20
Recruiting
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
NCT06979336Ulcerative Colitis
Genentech, Inc.
Phase 2
224
Kashiwa-shi, Fukuoka, Fukuyama-shi, Kanazawa, Takamatsu, Osaka, Saga, Fujidera-shi
2025-09-29
Recruiting
A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged โ‰ฅ40 to โ‰ค85 Years With Chronic Obstructive Pulmonary Disease.
NCT07053423Chronic Obstructive Pulmonary Disease
DrugDupilumab
Sanofi
Phase 4
218
Ube, Kyoto, Osaka
2025-09-22
Recruiting
LUPKYNIS Drug-use Results Survey
NCT07053891Lupus Nephritis
DrugsVoclosporin·Lupkynis
Otsuka Pharmaceutical Co., Ltd.
Observational
400
Osaka
2025-09-17
Recruiting
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
NCT07029828Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
140
Sendai, Hamamatsu, Mitaka, Osaka
2025-09-10
Recruiting
Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)
NCT07048262Non-cystic Fibrosis Bronchiectasis
CSL Behring
Phase 2
450
Chikushino-shi, Fukuoka, Ibaraki, Iizuka-shi, Kyoto, Mie, Osaka, Shimonoseki-shi
2025-09-03
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
NCT07023289Colorectal Cancer
DrugTelisotuzumab Adizutecan
AbbVie
Phase 2
140
Nagoya, Kashiwa-shi, Fukuoka, Gifu, Yokohama, Sendai, Osaka, Sunto-gun
2025-09-02
Recruiting
A Real World Study to Globally Assess Disease Burden in Adolescent and Adult Participants With Alopecia Areata, Vitiligo, or Hidradenitis Suppurativa
NCT07136467Non-Segmental Vitiligo (NSV), Alopecia Areata, Hidradenitis Suppurativa
AbbVie
Observational
2,795
Ebina-shi, Osaka, Mitaka-shi, ลŒta-ku
2025-09-02
Recruiting
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
NCT06920004Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
DrugsEmpasiprubart·IVIG
argenx
Phase 3
218
Aomori, Bunkyล City, Chลซลku, Hiroshima, Izunokuni, Osaka, Saga, Shimotsuke
2025-08-22
Recruiting
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT07005154Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
DrugsASP5541·Abiraterone acetate·Prednisolone·Prednisone
Astellas Pharma Global Development, Inc.
Phase 2
218
Kashiwa, Sunto-gun, Bunkyo-ku, Koto, Fukuoka, Osaka
2025-08-19
Recruiting
A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
NCT06948318Immune Thrombocytopenic Purpura (ITP)
DrugMezagitamab
Takeda
Phase 3
150
Chuo-ku, Narashino-shi, Ibaraki, Yokohama, Sendai, Hirakata-shi, Osaka, Suita-shi
2025-08-14
Active, closed
A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
NCT07170644Desmoid Tumor, Aggressive Fibromatosis
DrugNirogacestat
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase 2
20
Nagoya, Chuo Ku, Osaka
2025-08-08
Recruiting
A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
NCT07098338Non-Small Cell Lung Cancer
DrugsRamucirumab·Rilvegostomig·Datopotamab Deruxtecan
AstraZeneca
Phase 2
278
Bunkyล City, Fukuyama-shi, Kobe, Kurume-shi, Kyoto, Osaka, Sakaishi, Shinjuku-ku
2025-08-07
Recruiting
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
NCT07114601Breast Neoplasms, Colorectal Neoplasms, Prostate Neoplasm, Endometrial Neoplasms
Eli Lilly and Company
Phase 1
421
Chiba, Kyoto, Osaka
2025-08-06
Active, closed
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
NCT07029711Severe Alopecia Areata
DrugsRitlecitinib higher·Ritlecitinib lower
Pfizer
Phase 3
208
Sendai, Niigata, Hamamatsu, Mitaka, Osaka
2025-07-31
Recruiting
A Study of Vosoritide Versus Placebo in Children With Hypochondroplasia Aged 0 to < 36 Months
NCT07126262Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 2
60
Kumamoto, Osaka, Tokyo, Tottori
2025-07-30
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
NCT06765109Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
DrugsNeladalkib·Alectinib
Nuvalent Inc.
Phase 3
450
Fukuoka, Chikusa, Nagaizumi-chล, Okayama, Osaka, Sakai, Tokyo, Wakayama
2025-07-17
Recruiting
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
NCT07069712Gastroesophageal Adenocarcinoma
DrugsSonesitatug Vedotin·Calcium folinate·Rilvegostomig·Trastuzumab deruxtecan
AstraZeneca
Phase 2
100
Chลซลku, Fukuoka, Hidaka-shi, Kashiwa, Kitaadachi-gun, Kลtoku, Nagoya, Osaka
2025-07-17
Active, closed
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
NCT07015983Lupus Erythematosus, Systemic, Lupus Nephritis
DrugsZola-cel·Fludarabine·Cyclophosphamide
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 2
89
Sapporo, Yokohama, Bunkyo-ku, Shinjuku-ku, Chiba, Fukuoka, Okayama, Osaka
2025-07-14
Recruiting
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375Heart Failure
DrugCDR132L
Novo Nordisk A/S
Phase 2
200
Bunkyo-ku, Tokyo, Hamamatsu-shi, Shizuoka, Himeji-shi, Hyogo, Ibaraki, Kanagawa, Kita-gun, Kagawa, Kobe-shi, Hyogo, Osaka
2025-06-30
By invitation
Global Open-Label Extension Study of Del-desiran for the Treatment of DM1
NCT07008469Myotonic Dystrophy Type 1, DM1, Myotonic Dystrophy, Myotonia
Avidity Biosciences, Inc.
Phase 3
199
Aomori, Osaka, Tokyo
2025-06-26
Recruiting
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer
NCT06976944Recurrent Triple-Negative Breast Cancer
DrugsBevacizumab·Paclitaxel·Pembrolizumab
Yukinori Ozaki
Phase 2
24
Nagoya, Kashiwa-shi, Gifu, Hiroshima, Sapporo, Akashi-shi, Okayama, Osaka
2025-06-24
By invitation
Long-Term Extension Study of Vosoritide to Treat Children With Hypochondroplasia
NCT07073014Hypochondroplasia
DrugVosoritide
BioMarin Pharmaceutical
Phase 3
140
Osaka, Tokushima, Tokyo, Tottori
2025-06-20
Active, closed
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata
NCT07023302Alopecia Areata
DrugUpadacitinib
AbbVie
Phase 3
125
Nagoya, Kurume-shi, Kahoku-gun, Ebina-shi, Miyagi-gun, Sendai, Niigata, Osaka
2025-06-19
Recruiting
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
NCT06885034Gastrointestinal Neoplasms
DrugRisvutatug Rezetecan
GlaxoSmithKline
Phase 1/2
451
Aichi, Chiba, Hokkaido, Osaka, Tokyo
2025-06-11
Recruiting
A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD
NCT07038200Facioscapulohumeral Muscular Dystrophy, FSHD, FSHD - Facioscapulohumeral Muscular Dystrophy, FSHD1
DrugDel-brax
Avidity Biosciences, Inc.
Phase 3
200
Osaka, Sendai, Tokyo
2025-06-10
Recruiting
A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome
NCT06872125Dravet Syndrome
DrugZorevunersen
Stoke Therapeutics, Inc
Phase 3
170
Fukuoka, Hokkaido, Kyoto, Nagoya, Niigata, Okayama, Osaka, Shimotsuke
2025-06-04
Rows per page Showing 1–100 of 345
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-japan/city/osaka

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,472 studies in total at the last sync on 26 Sep 2026, 19:48 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 345 of those studies with a site in Osaka.

How many clinical trials are recruiting in Osaka?

162 of the 345 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:48 UTC sync. A further 2 have not yet opened recruitment, 172 are active but closed to new participants, and 9 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Osaka), 345 studies
PhaseStudiesRecruitingShare
Phase 31606846.4%
Phase 2693120%
Observational34219.9%
Phase 1/225187.2%
Phase 12396.7%
Phase 2/31454.1%
Not applicable1263.5%
Phase 4842.3%

Most active sponsors

Lead sponsors with the most studies (Osaka)
Lead sponsorStudiesRecruiting
AstraZeneca187
Eli Lilly and Company1610
GlaxoSmithKline159
Novartis Pharmaceuticals144
AbbVie137
Janssen Research & Development, LLC136
Pfizer135
Hoffmann-La Roche123
Merck Sharp & Dohme LLC103
Takeda86
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.